Trinity Life Sciences, a leader in strategy, insights, and analytics for the life sciences sector, has announced an enhancement to its HTA Vision offering.
HTA Vision with Generative AI
This upgrade leverages generative AI to quickly extract pertinent information from health technology assessments (HTAs). The platform also incorporates expert analyses. This integration streamlines the information-gathering process for any therapeutic area or drug class.
By not only locating but also summarizing key information with generative AI (GenAI), HTA Vision transforms complex documents into clear, comprehensive overviews. The goal is to assist Global Market Access leaders within life sciences to make informed decisions.
Monica Martin de Bustamante is Senior Partner and Head of Advisory at Trinity Life Sciences.
HTA outcomes are often lengthy and intricate documents. This makes them difficult to promptly analyze. The insights provided by HTA Vision allow leaders to apply the learnings to day-to-day decision-making. Expertise in countries, agencies, therapeutic classes, and lifecycle stages is essential to provide context. This enables actionable recommendations for a specific brand.
Monica Martin de Bustamante, Senior Partner and Head of Advisory at Trinity Life Sciences, explained, “Especially in the EU, market standards and complexities are increasing, which is making the environment more challenging for pharma. Combining artificial intelligence with human expertise streamlines and simplifies payer decision analysis without losing the tailored interpretations and deep insights from experts on how health authorities are evaluating products.”
Max Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access & Pricing practice, added, “Strategic decisions for clinical development and evidence generation are made by life sciences leaders on a daily basis and need to be informed by the latest market intelligence. Trinity HTA Vision allows users to position themselves for success in a global payer landscape that can be fickle and demanding—the addition of GenAI provides users with insights on HTA drivers at their fingertips.”
Key Features of Trinity HTA Vision
Trinity HTA Vision offers tailored solutions. These provide timely, strategic market access insights, and impactful interpretation of payer decisions globally. Offerings include:
- A cloud-based HTA dashboard with GenAI
- Flash alerts
- HTA decision digests
- Readouts of key events
HTA Vision delivers expert insights, curated by experts with extensive commercialization, global HTA, and access knowledge. Deliverables are flexible, scalable, and customized to each client’s needs and objectives.
Virtual Demo
A virtual demo will take place on March 13th. The demo, titled “HTA Vision with GenAI,” will feature Trinity experts Max Hunt and Andreia Ribeiro.
- They will demonstrate Trinity HTA Vision’s GenAI capabilities.
- They will discuss how the technology meets expert analysis requirements.
Life sciences executives are invited to register for the virtual demo.
About Trinity Life Sciences
With almost 30 years of experience, a best-in-the-business team, and unparalleled access to data and analytics, Trinity Life Sciences is a modern partner for companies in the life sciences industry. Trinity integrates strategy, insights, and analytics to support clinical and commercial decision-making for life science executives.
For additional information, visit TrinityLifeSciences.com.
Media Contact: Michele Wlodarczyk Trinity Life Sciences mwlodarczyk@trinitylifesciences.com
